By Will Feuer

Abbott Laboratories said Wednesday that it has received clearance from the U.S. Food and Drug Administration for its new heart mapping platform.

Abbott's EnSite X EP System with EnSite Omnipolar Technology creates detailed three-dimensional maps of the heart to help physicians better treat abnormal heart rhythms, or cardiac arrhythmias, the company said.

"These models provide a way to precisely identify areas that are causing problems, so physicians can better treat those abnormal heart rhythms, and preserve healthy tissue," said Mike Pederson, senior vice president of electrophysiology at Abbott.

Write to Will Feuer at Will.Feuer@wsj.com

(END) Dow Jones Newswires

January 12, 2022 09:26 ET (14:26 GMT)

Copyright (c) 2022 Dow Jones & Company, Inc.
Abbott Laboratories (NYSE:ABT)
Gráfico Histórico do Ativo
De Mar 2024 até Abr 2024 Click aqui para mais gráficos Abbott Laboratories.
Abbott Laboratories (NYSE:ABT)
Gráfico Histórico do Ativo
De Abr 2023 até Abr 2024 Click aqui para mais gráficos Abbott Laboratories.